Síndrome Sezary

Extracorporeal Photopheresis in Sezary Syndrome

NCT05157581

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

NCT06588868

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

NCT07003100

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

NCT04256018

Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.

NCT04904146

NCT05157581 · Extracorporeal Photopheresis in Sezary SyndromeRecrutando

🟢 Recrutando agora

5 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT06588868 · Systemic Therapies in the Treatment of Cutaneous T-cell Lymp…Recrutando

NCT07003100 · A Prospective, US-based Study Assessing Mogamulizumab-associ…Recrutando

NCT04256018 · Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Myco…Recrutando

NCT04904146 · Predictive and Prognostic Biomarkers in Patients With Mycosi…Recrutando

Outros ensaios clínicos

33 ensaios clínicos encontrados, 10 ativos.

Distribuição por fase

NCT04652960 · Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB M…Ativo

PHASE1

NCT04960618 · Pembrolizumab in Combination With Gemcitabine in People With…Ativo

NCT05944562 · Tulmimetostat (DZR123) in Patients With Mycosis Fungoides an…Ativo

PHASE1

NCT05455931 · Real World Observational Study of Poteligeo in Adult Patient…Ativo

NCT06651203 · Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézar…Em breve

NCT02953301 · Resminostat for Maintenance Treatment of Patients With Advan…Concluído

NCT04676087 · Mogamulizumab and Extracorporeal Photopheresis for the Treat…Encerrado

PHASE1, PHASE2

NCT02836886 · VircapSeq Virus Detection in Sézary SyndromeConcluído

NCT03063632 · Testing the Combination of Two Experimental Drugs MK-3475 (P…Concluído

NCT02811783 · Naloxone Hydrochloride Study for Relief of Pruritus in Patie…Encerrado

PHASE3

NCT02822586 · TSEB and Brentuximab for Treatment of Mycosis Fungoides & Se…Concluído

PHASE1

NCT02542124 · NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Tota…UNKNOWN

NCT01396070 · Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoi…Concluído

NCT00748319 · Killer Immunoglobulin-Like Receptor Transcripts Expression f…Concluído

NA

Ver todos no ClinicalTrials.gov

🧪 Está conduzindo uma pesquisa?

Divulgue para pacientes e familiares que acompanham esta doença.

Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações

1.111 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 1.111

#1

Inducible Costimulator and Its Ligand Promote Proliferation and Migration of Tumor Cells in Cutaneous T-Cell Lymphoma.

International journal of molecular sciences2026 Jan 30

Inducible costimulator (ICOS) is a costimulatory immune checkpoint receptor expressed on activated T-cells, while the ICOS ligand (ICOSL) is expressed on antigen-presenting cells. The ICOS-ICOSL axis promotes the survival of memory and effector T-cells and induces several immune responses. In addition, the ICOS-ICOSL interaction induces cell proliferation, cell survival, and cytokine production. The roles of ICOS and ICOSL in cutaneous T-cell lymphoma (CTCL) are unclear. In this study, we examined the roles of ICOS and ICOSL in CTCL. The tumor cells co-expressed ICOS and ICOSL, and the upregulated expression of ICOS and ICOSL reflected disease severity. Anti-ICOS and anti-ICOSL neutralizing antibodies inhibited both the in vitro and in vivo proliferation of CTCL cell lines. The anti-ICOSL neutralizing antibodies induced apoptosis and suppressed CCR4 expression on tumor cells, inhibiting CCR4-CCL17-mediated migration. These results suggest that the ICOS-ICOSL axis plays an essential role in CTCL pathogenesis, and targeting the ICOS-ICOSL axis could be a viable strategy for treating CTCL.

#2

Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

The Lancet. Haematology2026 Feb

In advanced-stage cutaneous T-cell lymphoma (CTCL), current therapeutic options rarely provide long-lasting responses. We aimed to evaluate the efficacy and safety of a histone deacetylase inhibitor, resminostat, as maintenance therapy in patients with advanced-stage mycosis fungoides or Sézary syndrome, in whom disease control had been previously met. We conducted a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial (RESMAIN) at 55 medical centres in Austria, Belgium, France, Germany, Greece, Italy, the Netherlands, Poland, Spain, Switzerland, the UK, and Japan. Adult patients (aged ≥18 years) with histologically confirmed, stage IIB-IVB mycosis fungoides or Sézary syndrome; an Eastern Cooperative Oncology Group performance status score of 0-2; and disease control after at least one previous systemic therapy or total skin electron beam were eligible for inclusion. Patients were randomly assigned to receive either oral resminostat (600 mg) or matching oral placebo once daily for 5 days, followed by a treatment-free period of 9 days, within a 14-day treatment cycle. Randomisation was stratified by disease stage (IIB-IVA1 vs IVA2-IVB) and remission status following previous therapy (complete or partial response vs stable disease) by use of a dynamic block allocation process (block size 100 patients). Participants, investigators, site staff, and study personnel involved in outcome assessment and data analysis were masked to group assignment. Patients with disease progression during masked treatment were unmasked; patients on placebo were offered open-label resminostat. Treatment was continued until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival, defined as the time from randomisation to disease progression or death from any cause (whichever occurred first), analysed by intention to treat. This trial is registered with ClincalTrials.gov (NCT02953301) and has been completed. Between Jan 9, 2017, and May 11, 2022, 234 patients were screened for eligibility, of whom 201 (86%) patients were randomly assigned: 100 (50%) to resminostat and 101 (50%) to placebo. 123 (61%) participants were men and 78 (39%) were women, with a median age of 64 years (range 30-87). Most participants (173 [86%]) were White, 19 (9%) were Asian (mainly Japanese), two (1%) were Black, and seven (3%) were either another race or ethnicity, or did not disclose these data. Median progression-free survival was 8·3 months (95% CI 4·2-15·7) in the resminostat group and 4·2 months (2·8-6·4) in the placebo group (HR 0·62 [95% CI 0·42-0·92]; p=0·015). Median follow-up time for progression-free survival was 11·2 months (95% CI 5·6-19·6) in the resminostat group and 17·0 months (13·9-30·5) in the placebo group. Adverse events were reported in 96 (96%) patients receiving resminostat and in 81 (80%) patients receiving placebo. Serious adverse events occurred in 19 (19%) patients in the resminostat group, 11 (11%) of which were considered related to treatment, and in 12 (12%) in the placebo group, of which one (1%) was considered to be treatment-related. Adverse events of grade 3 or above occurred in 38 (38%) patients in the resminostat group and in 15 (15%) patients in the placebo group. The most common treatment-related adverse events were nausea (68 [68%] in the resminostat group vs six [6%] in the placebo group), diarrhoea (44 [44%] vs nine [9%]), vomiting (32 [32%] vs one [1%]), and fatigue (29 [29%] vs 14 [14%]). There were no treatment-related deaths. These findings support the beneficial effect of resminostat maintenance therapy in patients with advanced CTCL. The overall safety profile of resminostat was acceptable, with gastrointestinal side-effects occurring most frequently. Anti-emetic prophylaxis should be considered in the future to manage side-effects and to improve tolerability and adherence to maintenance therapy. 4SC AG.

#3

Protocol for a mixed-methods modified Delphi study for the development of a core domain set to assess the health-related quality of life of patients with mycosis fungoides and Sézary syndrome in clinical trials.

BMJ open2026 Feb 06

Cutaneous T cell lymphoma (CTCL) is a group of non-Hodgkin lymphomas that primarily affects the skin and can mimic inflammatory dermatoses. Unlike many skin diseases, CTCL can lead to disabling symptoms, and advanced CTCL can even be fatal. Early studies investigating health-related quality of life (HRQOL) in patients with mycosis fungoides (MF) and Sézary syndrome (SS), common subtypes of CTCL, demonstrated significant impairment across numerous domains. The aim of this current study is to develop a core domain set (CDS) to identify the essential aspects of MF/SS that influence HRQOL that should be measured in therapeutic clinical trials. In the future, this set of core concepts will be used to identify the best patient- reported outcome measure(s) (PROM) for HRQOL for MF/SS clinical research. Multiple strategies will be used to generate candidate concepts: systematic review of the literature, qualitative study and a survey study of healthcare providers. A Delphi consensus process including a comprehensive group of stakeholders (patients, caregivers/care partners, a multidisciplinary group of healthcare professionals, patient advocacy groups, pharmaceutical industry representatives, methodologists and government agencies) will be used to achieve consensus. Statistical corrections for multiple significance testing and false positive findings will be undertaken. The study was submitted for and received institutional review board approval at the University of Washington (IRB# STUDY00018890 and STUDY00019407). Informed consent will be obtained from all participants where necessary. We will disseminate our findings through peer-reviewed, open access publications and presentations at national/international conferences. We will provide a plain language summary in lay terms for patients and families to patient advocacy groups for distribution to their network. The protocol is registered in the Core Outcome Measures in Effectiveness Trials (COMET) database.

#4

T-Cell Receptor Clonotypes and Aggressive Subtypes in Cutaneous T-Cell Lymphoma.

JAMA dermatology2026 Jan 01

T-cell receptor (TCR) clonotype patterns across disease stages and histologic subtypes in mycosis fungoides (MF) and Sézary syndrome (SS) remain poorly characterized, limiting their use in risk stratification. To assess the association of TCR β (TCRB) and γ (TCRG) clonotypes with disease stage, folliculotropism, large-cell transformation, and overall survival (OS) as well as clonal abundance (percentage of total reads) with immune checkpoint expression. This retrospective cohort study conducted at City of Hope (Duarte, California) included patients with stage IA to IVB MF/SS who underwent TCR next-generation sequencing on lesional skin biopsy specimens collected between June 2020 to October 2024; duplicate samples were excluded. Analyses were performed from November 2024 to April 2025. Associations between clinical and genetic categorical variables were evaluated using the Fisher exact test. OS was analyzed using Kaplan-Meier estimates, with univariate and multivariable models applied to assess prognostic factors. Of the 125 patients (42 female [33.6%] and 74 male individuals [66.4%]; mean [SD] age, 62.4 [15.9] years) who underwent TCR sequencing, at least 1 clonal TCRB and/or TCRG gene segment was identified in 98 patients (78%). Clonal TCRB and TCRG segments were detected in 72 (57.6%) and 92 patients (73.6%), respectively. The clonal Vb20 segment was significantly associated with folliculotropism and concurrent large-cell transformation compared with classic MF/SS (7 of 17 [41%] vs 0 of 30 [0%]; P < .001), marginally significantly associated with advanced-stage MF/SS compared with early-stage MF (8 of 38 [21%] vs 0 of 34 [0%]; P = .01). Clonal Vg8 was significantly associated with advanced-stage MF/SS compared with early-stage MF (25 of 53 [47%] vs 8 of 39 [21%]; P = .01) and correlated with poorer OS. Additionally, the higher percentage of total reads for TCRG was positively correlated with increased expression of immune checkpoints programmed cell death 1 and inducible T-cell costimulator but not with programmed cell death ligand 1. This cohort study's analysis of TCRB and TCRG repertoires identified specific clonotypes that were associated with more aggressive subtypes and poorer survival in patients with MF/SS. Incorporating TCR sequencing into clinical practice may enhance risk stratification, enabling earlier identification of high-risk patients who could benefit from closer monitoring and timely implementation of more intensive treatment strategies in the disease course to improve clinical outcomes.

#5

Safety of Concurrent Systemic Therapy and Total Skin Electron Therapy in Cutaneous T-Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia2026 Mar 01

To evaluate the safety and outcomes of total skin electron therapy (TSET) delivered with concurrent systemic therapy (CS) for cutaneous T-cell lymphoma (CTCL). We retrospectively identified CTCL patients (including Sézary syndrome and mycosis fungoides) receiving TSET from 2013 to 2023. Acute toxicities were graded per CTCAE v5.0 and defined as new or worsened (N/W) from baseline. Cutaneous response was assessed at 2-8 weeks and 6 months post-TSET. Analyses of toxicity and response were performed per TSET course and classified as CS if any systemic agent was administered during treatment. Survival outcomes were estimated using Kaplan-Meier methods in per-patient analyses using one index course per patient, with time measured from the start of TSET. A total of 121 TSET courses were analyzed, including 75 (62%) with CS and 46 (38%) without concurrent systemic therapy (NCS). Median follow-up was 21 months overall and longer for CS courses (28 vs. 16 months; P = .019). Nearly all courses experienced ≥1 N/W toxicity, most of which was low grade. High-grade toxicities occurred in 13% of CS and 26% of NCS courses (P = .080), with no grade ≥4 events. Overall, toxicity burden and symptom outcomes were similar between groups. Toxicity severity appeared comparable across commonly used systemic therapy classes; one patient receiving concurrent methotrexate experienced disproportionate toxicity. Early overall response rates at 2-8 weeks were 90% (CS) and 92% (NCS) (P = .138). In per-patient analyses, median progression-free survival was 8.61 versus 6.08 months (log-rank P = .325), and 24-month overall survival was 85.7% versus 68.3% (log-rank P = .098) for CS and NCS, respectively. TSET can be delivered safely with most commonly used CS therapies in CTCL.

Publicações recentes

Targeting Cutaneous T-cell lymphoma in non-hodgkin lymphoma: What's new for investigational agents?

Expert Opin Investig Drugs2026 Apr 16

Mogamulizumab-Induced Linear IgA Bullous Dermatosis in a Patient With Sézary Syndrome.

Australas J Dermatol2026 Apr 14

Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group.

J Allergy Clin Immunol2026 Apr 10

Ex-vivo Sézary Syndrome patient tumour cells are sensitive to ATR inhibition.

J Invest Dermatol2026 Apr 8

Conversational Artificial Intelligence-Enabled Molecular Characterization of Sézary Syndrome Reveals Distinct Pathway-Level Alterations Compared with Non-Sézary Cutaneous T-Cell Lymphoma.

medRxiv2026 Mar 10

Ver todas no PubMed

📚 EuropePMC1.318 artigos no totalmostrando 196

Safety of Concurrent Systemic Therapy and Total Skin Electron Therapy in Cutaneous T-Cell Lymphoma.

Mogamulizumab-associated lymphadenopathy masquerading as lymphoma progression.

Journal of cutaneous medicine and surgery

Leonine Facies in Sézary Syndrome.

Journal of the European Academy of Dermatology and Venereology : JEADV

Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.

Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC-CLTG.

Journal of the European Academy of Dermatology and Venereology : JEADV

Mapping malignant T-cell states and immune circuits in Sézary syndrome by single-cell analysis.

Persistence of sex differences and stable trends in mortality in patients with mycosis fungoides and Sézary syndrome in Spain (1983-2022).

Medicina clinica

Mycosis fungoides and Sézary syndrome.

Type 2 diabetes and risk of non-Hodgkin lymphoma and multiple myeloma: a pooled analysis.

JNCI cancer spectrum

International journal of molecular sciences

Inducible Costimulator and Its Ligand Promote Proliferation and Migration of Tumor Cells in Cutaneous T-Cell Lymphoma.

Laboratory Evaluation of Peripheral Blood Involvement in Mycosis Fungoides and Sézary Syndrome: Evolution of Flow Cytometry and Morphology Quantification and Interpretation.

Efficacy and tolerability of mogamulizumab in mycosis fungoides and Sézary Syndrome: a monocentric retrospective study.

Frontiers in oncology

Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

The Lancet. Haematology

Protocol for a mixed-methods modified Delphi study for the development of a core domain set to assess the health-related quality of life of patients with mycosis fungoides and Sézary syndrome in clinical trials.

BMJ open

A historical review of mycosis fungoides: from Alibert to mogamulizumab.

Skin health and disease

The Journal of investigative dermatology

Diverse transcriptomic and mutational patterns but limited functional pathway alterations in patient-derived Sézary syndrome cells.

Journal of drugs in dermatology : JDD

Racial Disparities in United States Clinical Trial Enrollment for Mycosis Fungoides and Sézary Syndrome.

Journal of comparative pathology

Sézary syndrome arising from cutaneous epitheliotropic T-cell lymphoma, resembling human folliculotropic mycosis fungoides, in a dog.

International journal of dermatology

Diagnostic Implications of Dupilumab-Refractory Atopic Dermatitis: Risk of Underlying Cutaneous T-Cell Lymphoma and the Role of Skin Biopsy.

Neutrophil-Galectin-9 Axis Linking Innate and Adaptive Immunity in ATL, Sézary Syndrome, COVID-19, and Psoriasis: An AI-Assisted Integrative Review.

Reports (MDPI)

How I manage mycosis fungoides and Sézary syndrome: Current controversies and unmet needs.

Novel isochromosome 7q and NOTCH1 mutation in an 88-year-old male with Sézary syndrome.

Sézary syndrome presenting as vitiligo-like leukoderma with response and repigmentation to mogamulizumab and extracorporeal photopheresis.

Delayed Diagnosis of Sézary Syndrome: Lessons From a Psoriasiform Presentation.

Clinical case reports

Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network.

Acta dermato-venereologica

Incidence and Mortality of Mycosis Fungoides and Sezary Syndrome: A Nationwide Registry Study in Finland.

Therapeutic advances in hematology

Mogamulizumab plus etoposide in the management of mycosis fungoides with blood involvement: a case report.

Journal of cancer research and therapeutics

Initial experience with a novel device for supporting a debilitated patient during total skin electron beam therapy.

Nuclear medicine review. Central & Eastern Europe

[18F]FDG PET/CT revealing extensive cutaneous involvement in Sézary syndrome.

Frontiers in veterinary science

Case Report: Dose-dependent response to oclacitinib in a dog with Sézary syndrome.

Actas dermo-sifiliograficas

Translation, Cross-cultural Adaptation, Correlation With Other PROMs and Validation of the MF/SS-CTCL-QoL Questionnaire on Quality of Life in Mycosis Fungoides (MF) and Sézary Syndrome (SS).

Relapsed/refractory mycosis fungoides and Sezary syndrome: biology, clinical manifestations and therapeutic options.

Leukemia & lymphoma

Clinical Implications of the Skin Microbiota in the Therapy of Cutaneous T Cell Lymphoma: A Scoping Review.

Dermatology and therapy

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Recent trends of incidence and mortality of cutaneous lymphomas in Germany.

Disparities in immunotherapy treatment for mycosis fungoides and Sézary syndrome in the National Cancer Database.

American journal of ophthalmology case reports

Unusual presentation of fungal keratitis and endogenous endophthalmitis in Sézary syndrome: a case report.

Dermatology practical & conceptual

Retrospective Analysis of Second Primary Malignancies in Patients with Mycosis Fungoides and Sézary Syndrome in Croatia.

OX-40 signaling promotes tumorigenesis in CTCL by regulating ERK activation.

Journal of the European Academy of Dermatology and Venereology : JEADV

scRNA-Seq reveals anti-lymphoma immune responses in mogamulizumab-associated skin eruptions.

Cancer immunology research

IL4/IL13 Inhibition via Dupilumab Reduces Malignant T-cell Proliferation and Promotes Antitumor Immunity in Sézary Syndrome.

Journal of clinical medicine

The Evaluation of Skin Infiltration in Mycosis Fungoides/Sézary Syndrome Using the High-Frequency Ultrasonography.

T-Cell Receptor Clonotypes and Aggressive Subtypes in Cutaneous T-Cell Lymphoma.

Indian journal of dermatology, venereology and leprology

A rare case of Sézary syndrome - A diagnostic challenge.

Extracorporeal photopheresis therapy rapidly changes the cytokine profile and tumor microenvironment in cutaneous T cell lymphoma.

Co-expression of CD30 and SLFN11 serves as a dual biomarker for the treatment of cutaneous T-cell lymphoma.

NAR cancer

Lymph node detection of monoclonal T-cell population correlates with poorer prognosis in mycosis fungoides and Sèzary syndrome.

The American journal of surgical pathology

Dual TRBC1-CD3 Immunohistochemistry Shows High Diagnostic Utility in Differentiating Mycosis Fungoides/Sezary Syndrome From Reactive Inflammatory Dermatoses in Skin Biopsies.

Bone marrow transplantation

Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee.

Racial differences in mycosis fungoides and Sézary syndrome: A multicenter cohort study.

Journal of the European Academy of Dermatology and Venereology : JEADV

Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.

American journal of clinical pathology

Expanded CD4+CD57+ T-large granular lymphocytes: A diagnostic pitfall in blood staging of mycosis fungoides/Sézary syndrome.

A to F Think MF! A memory aid for early recognition of mycosis fungoides/Sézary syndrome.

Weekly dosing schedule of brentuximab vedotin is well tolerated in mycosis fungoides/Sézary syndrome.

Revista espanola de cardiologia (English ed.)

Sézary syndrome as an unusual cause of Loeffler endocarditis.

European journal of dermatology : EJD

Mogamulizumab-associated rash and lymphocytopenia coinciding with treatment response of Sézary syndrome.

Quality and duration of responses with mogamulizumab in cutaneous T-cell lymphomas: Insights into long-lasting outcomes.

An Update on Single-Cell RNA Sequencing in Illuminating Disease Mechanisms of Cutaneous T-Cell Lymphoma.

Targeted Radiotherapy in Primary Cutaneous Lymphomas: Precision, Efficacy, and Evolving Strategies.

Recurrence of mogamulizumab-associated rash in patients with relapsed erythrodermic cutaneous T-cell lymphoma after retreatment with mogamulizumab.

Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World Cohort.

Cancer pathogenesis and therapy

Economic burden and health-related quality of life in Chinese patients with mycosis fungoides and Sézary syndrome.

Expressed mutated genes in Sezary syndrome and their potential prognostic value in patients treated with extracorporeal photopheresis.

Synergistic Efficacy of Chidamide and LB100 in Sézary Syndrome via TNC Downregulation and PI3K/AKT/mTOR Dephosphorylation.

Cancer science

High-Throughput Sequencing and Estimated Relapse Risk in Patients With Sézary Syndrome.

Janus kinase inhibitors - a role for the treatment of cutaneous T-cell lymphomas?

Oncology reviews

Unraveling the role of chemokines in cutaneous T-cell lymphoma: expression levels at different stages.

Turkish journal of haematology : official journal of Turkish Society of Haematology

Clinical and Prognostic Features of Erythrodermic Cutaneous T-Cell Lymphoma: A Retrospective Study of 35 Patients.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Low-dose total skin electron beam therapy in erythrodermic mycosis fungoides and Sézary syndrome: Results From the Prospective S-MISR Study.

Case report of non-gene editing CD7 CAR T cell therapy in CD7+ Sézary syndrome: preclinical validation and first-in-human use.

CRISPR-Cas9 screen reveals that inhibition of enhancer of zeste homolog 2 sensitizes malignant T cells to dimethyl-fumarate-induced cell death.

The FEBS journal

The Journal of dermatology

Pruritus Is an Indicator for Quality of Life in Cutaneous T-Cell Lymphoma.

Postepy dermatologii i alergologii

Psychosocial burden of patients with mycosis fungoides and Sézary syndrome compared to other dermatological patients. Pilot study.

A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification.

Blood

Expert review of clinical immunology

Immune pathways, current and potential therapies in Mycosis fungoides and Sezary syndrome.

Pharmacovigilance study for the identification of mogamulizumab-induced immune-related adverse events using a real-world database.

The oncologist

Expert review of anticancer therapy

New nonchemotherapy treatment options for cutaneous T-cell lymphomas an update.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Acneiform type of mogamulizumab-associated rash.

Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma: A Nonrandomized Clinical Trial.

The Israel Medical Association journal : IMAJ

Coexistence of Mycosis Fungoides and Photosensitive or Autoimmune Diseases. The Therapeutic Challenge: A retrospective Case Series from a Tertiary Referral Center.

Increased mortality due to lymphoma and infections in patients with mycosis fungoides or Sézary syndrome: a Swedish nationwide population-based cohort study.

High Prevalence and Risk Factors for Infection with Human T-Lymphotropic Viruses 1 and 2 in the Municipality of Ananindeua, Pará, Northern Brazil.

Viruses

The Journal of investigative dermatology

CCR8 Immunohistochemistry Highlights CCR8 as a Diagnostic and Therapeutic Biomarker in Cutaneous T-Cell Lymphoma.

International journal of molecular sciences

Structural Insights into the ADCC Mechanism and Resistance of Mogamulizumab, a First-in-Class Anti-CCR4 Therapy for Cutaneous T Cell Lymphoma.

Large-cell transformation of mycosis fungoides: Patterns of care and patient outcomes.

Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphoma.

Immunotherapy

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies.

Blood neoplasia

Postepy dermatologii i alergologii

Classical and biological treatments in mycosis fungoides/Sézary syndrome. New horizons in oncodermatology.

American journal of hematology

Mycosis Fungoides, Sézary Syndrome, and Cutaneous B-Cell Lymphomas: 2025 Update on Diagnosis, Risk-Stratification, and Management.

Expert opinion on biological therapy

An evaluation of denileukin diftitox for the treatment of relapsed or refractory cutaneous T-cell lymphoma.

Racial and Socioeconomic Disparities in Cutaneous T-Cell Lymphoma Survival: Insights From the National Cancer Database.

OX40-OX40L Axis in Cutaneous T-Cell Lymphomas: Pathogenic, Prognostic, and Potential Therapeutic Perspectives.

Biomolecules

Expert review of clinical immunology

Mycosis fungoides and IL-4/13 inhibitors: what is known and unmet needs.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Implementing total skin electron irradiation in radiotherapy: a structured change management approach.

Diagnostics (Basel, Switzerland)

Dermatoscopic Patterns in Mycosis Fungoides: Observations from a Case-Series Retrospective Analysis and a Review of the Literature.

Case Report: Cutaneous T-cell lymphoma associated with biologic therapy: three cases and a literature review.

Frontiers in medicine

[T follicular helper cell lesions and mimics in dermatopathology: From theory to practice].

Annales de pathologie

European journal of cancer (Oxford, England : 1990)

Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG "PARCT".

The American Journal of dermatopathology

Concomitant Squamous Cell Carcinoma and Mycosis Fungoides Within the Same Lesion: A Case Report and Literature Review.

Fatal mycosis fungoides, misdiagnosed as contact dermatitis.

EJNMMI reports

Laboratory investigation; a journal of technical methods and pathology

Maturation-Related and Functional-Associated Phenotypic Profile of Tumor T Cells in Mature/Peripheral T-Cell Neoplasms: Association With the Diagnostic Subtype of the Disease.

Journal of cutaneous pathology

Rare Concomitant Langerhans Cell Histiocytosis in a Patient With Folliculotropic Mycosis Fungoides.

The Journal of dermatology

Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T-Cell Lymphoma: A Real-World Single-Center Experience.

Drug- and Vaccine-Induced Cutaneous T-Cell Lymphoma: A Systematic Review of the Literature.

Journal of skin cancer

ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome.

Altered immune cell profiles in blood of mature/peripheral T-cell leukemia/lymphoma patients: an EuroFlow study.

Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome.

Journal of dermatological science

RN7SL1 overexpression promotes cell proliferation in cutaneous T-cell lymphoma via miR-34a-5p/MYCN axis.

Translational medicine @ UniSa

Clinical Utility of TRBC1 Addition in Multiparametric Flow Cytometry for T Cell Lymphoma Diagnosis.

American journal of hematology

Sézary Syndrome-Eosinophilia Explained by a Blood Film.

Therapeutic advances for cutaneous T-cell lymphoma.

Current neurology and neuroscience reports

Central Nervous System Manifestations of Cutaneous Lymphomas.

The real-world application of T-cell receptor constant beta-1 chain antibody assay in cutaneous T-cell lymphoma.

Increased risk of cutaneous squamous cell carcinomas in patients with Sézary syndrome: A nationwide multicenter retrospective study.

Identification of subgroups of early-stage mycosis fungoides patients with increased itch and impaired quality of life.

Frontiers in oncology

Acta dermato-venereologica

Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-world Single-centre Case Series.

Journal of cutaneous medicine and surgery

Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies.

Unveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell Lymphoma.

Current oncology reports

Italian journal of dermatology and venereology

Cutaneous T-cell lymphomas: a real-life experience of anticipated use of mogamulizumab in Italy.

Overall and Cause-Specific Mortality Among Patients With Cutaneous T-Cell Lymphoma in the United States.

EJHaem

Preclinical in vitro and in vivo evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomas.

Iranian journal of pathology

Diagnostic Approach to Adult Erythroderma: A Rare Case of Sezary Syndrome.

Estrogen receptor β stimulation as a possible novel therapeutic target for cutaneous T-cell lymphoma.

Blood advances

Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma.

The CD39/CD73/Adenosine and NAD/CD38/CD203a/CD73 Axis in Cutaneous T-Cell Lymphomas.

Cells

Dermatitis : contact, atopic, occupational, drug

Exploring the Link Between Dupilumab and Cutaneous T-Cell Lymphomas: A Systematic Review.

Sézary syndrome mimicking Steven-Johnson syndrome: A case report.

Medicine

Frontiers in cell and developmental biology

HDAC10 and its implications in Sézary syndrome pathogenesis.

The Journal of allergy and clinical immunology

Is dupilumab use in atopic dermatitis associated with cutaneous T-cell lymphoma?

Indian journal of dermatology, venereology and leprology

Mycosis fungoides and Sezary syndrome - Simplifying the approach for dermatologists. Part 2: Evaluation, staging, prognosis and treatment.

Therapeutic advances in hematology

Management of mycosis fungoides and Sézary syndrome with mogamulizumab in combination with psoralen plus UVA: two case reports.

The Journal of dermatological treatment

Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab.

Sézary syndrome with large cell transformation and T-follicular helper phenotype.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Is Kaposi sarcoma a novel comorbidity of cutaneous lymphoma? A systematic review of the literature.

Targeted dual biologic therapy for erythroderma of unknown etiology guided by high-parameter peripheral blood immunophenotyping.

Scientific reports

Treatment of Sezary syndrome with combination romidepsin and tofacitinib: A case report.

Current hematologic malignancy reports

Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).

Black patients with Mycosis fungoides and Sézary Syndrome experience worse health-related quality of life: A cross-sectional study.

Journal of clinical medicine

Could Residents Adequately Assess the Severity of Skin Lesions in Mycosis Fungoides/Sézary Syndrome? Evaluation of Interrater Agreement and Interrater Reliability of mSWAT.

Indian journal of dermatology, venereology and leprology

Mycosis fungoides and Sézary syndrome - Simplifying the approach for dermatologists. Part 1: Etiopathogenesis, clinical features and evaluation.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.

A Yale Dermatology perspective on cutaneous T cell lymphoma: Historic reflection to emerging therapies.

Clinics in dermatology

Seminars in radiation oncology

Breaking Down the Barriers for Patients With Cutaneous T-Cell Lymphoma: Current Controversies and Challenges for Radiation Oncologists in 2024.

The American Journal of dermatopathology

Differential Expression of p53 in Mycosis Fungoides, Sezary Syndromes, and Their Transformed Forms.

Immune Checkpoints and Their Inhibition in T-Cell Lymphomas.

Folia biologica

Hematology. American Society of Hematology. Education Program

Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas.

Hematology. American Society of Hematology. Education Program

The role of stem cell transplant (auto and allo) in PTCL and CTCL.

Acta dermato-venereologica

Sustained Complete Remission in Sézary Syndrome using Extracorporeal Photopheresis: A Multicentric Case Series.

Potential mogamulizumab-associated inflammatory bowel disease in cutaneous T-cell lymphoma management.

Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome.

Critical reviews in oncology/hematology

Skin barrier dysfunction in cutaneous T-cell lymphoma: From pathogenic mechanism of barrier damage to treatment.

Photodermatology, photoimmunology & photomedicine

A Retrospective Comparison Between Home and in-Office NB-UVB Efficacy for Patients With Mycosis Fungoides.

Haematogenous seeding in mycosis fungoides and Sézary syndrome: current evidence and clinical implications.

Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.

EClinicalMedicine

Nanopore Sequencing for T-Cell Receptor Rearrangement Analysis in Cutaneous T-Cell Lymphoma.

Journal of the Formosan Medical Association = Taiwan yi zhi

Cutaneous T-cell lymphoma: Consensus on diagnosis and management in Taiwan.

Folliculotropic mycosis fungoides with leukaemic involvement in middle childhood: a rare encounter.

BMJ case reports

Journal of cutaneous medicine and surgery

Use of Immune Checkpoint Inhibitors in Refractory Mycosis Fungoides and Sézary Syndrome: A Systematic Review.

Clinical Reasoning: Progressive Peripheral Neuropathy in a 66-Year-Old Woman With Sezary Syndrome.

Neurology

European journal of cancer (Oxford, England : 1990)

Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group.

The Tumor Microenvironment as a Therapeutic Target in Cutaneous T Cell Lymphoma.

Role of Retinoids and Their Analogs in the Treatment of Cutaneous T-cell Lymphoma: A Systematic Review.

Cureus

Genetic alteration of class I HLA in cutaneous T-cell lymphoma.

Blood

Real-world Use of Mogamulizumab Among Patients With Mycosis Fungoides and Sézary Syndrome Before and During COVID-19 in the United States.

Clinical therapeutics

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patients.

Mogamulizumab-induced bone granuloma.

Joint bone spine

Current oncology (Toronto, Ont.)

Mogamulizumab and Concomitant Hypofractionated Low-Dose Total Skin Electron Beam Therapy (2 × 4 Gy) in Cutaneous T-Cell Lymphoma: Proof of Principle, Report of Two Cases.

The Journal of investigative dermatology

Cutaneous T-Cell Lymphoma and Dupilumab Use: A Multifactorial and Complex Story.

Upadacitinib unmasks cutaneous T-cell lymphoma in atopic dermatitis.

Journal of the European Academy of Dermatology and Venereology : JEADV

Health-related quality of life in cutaneous T-cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome.

A Retrospective Cohort Study to Determine Real-World Treatment Patterns in Patients with Sézary Syndrome in the United States.

Oncology and therapy

Systemic treatments with monoclonal antibodies in mycosis fungoides and Sézary syndrome.

Dermatology reports

Bone marrow transplantation

Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an "outpatient" alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplantation.

Evaluation of Sézary cell marker expression and cell death behaviour upon in vitro treatment by flow cytometry in Sézary syndrome patients.

Experimental dermatology

European journal of dermatology : EJD

Mogamulizumab for Sézary syndrome: long-term remission with associated autoimmune haemolytic anaemia.

Gan to kagaku ryoho. Cancer & chemotherapy

[Persistent Effects of Mogamulizumab on Peripheral Blood Lesions after Treatment Completion in a Patient with Refractory Sézary Syndrome-A Case Report].

Assessing Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome: Unmet Needs.

On the Way to Curing Advanced-Stage Mycosis Fungoides/Sézary Syndrome.

Journal of hematopathology

Quantification of the median fluorescence intensity of CD3 and CD4 in mycosis fungoides/Sezary syndrome versus non-neoplastic control cases in peripheral blood.

Therapeutic advances in hematology

A case report of refractory advanced-stage mycosis fungoides: successful treatment and improved patient quality of life with mogamulizumab.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

The fifth edition of the WHO-Classification - what is new for cutaneous lymphomas?

Hematology/oncology clinics of North America

Cutaneous T-cell Lymphoma.

Development and psychometric properties of the Functional Assessment of Cancer Therapy-Cutaneous T-Cell Lymphoma (FACT-CTCL) instrument.

Improving disease-specific survival for patients with Sezary syndrome in the modern era of systemic therapies.

JAAD Game Changers: Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the US Cutaneous Lymphoma Consortium.

European journal of dermatology : EJD

Progression of CD8-positive Sézary syndrome from mycosis fungoides following dupilumab treatment.

Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.

EClinicalMedicine

JID innovations : skin science from molecules to population health

Whole-Transcriptome Sequencing-Based Profiling of the Cutaneous Virome in Patients with Secondary Immunodeficiency.

Journal of cutaneous pathology

Primary cutaneous EBV+ extranodal NK/T-cell lymphoma of gamma/delta T-cell lineage in the posttransplantation setting.

Hematology (Amsterdam, Netherlands)

A retrospective study of prognostic factors and treatment outcome in advanced-stage Mycosis Fungoides and Sezary Syndrome.

Actas dermo-sifiliograficas

[Translated article] Survival Analysis and Prognostic Factors in a Case Series of 148 Cutaneous T-Cell Lymphomas.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Mogamulizumab-associated rash - Case series and review of the literature.

Sézary Syndrome in West Sweden: Exploring Epidemiology, Clinical Features, and Treatment Patterns in a Registry-Based Retrospective Analysis.

The Journal of dermatological treatment

Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017-2019.

Updated cutaneous T-cell lymphoma TNMB staging criteria fail to identify patients with Sézary syndrome with low blood burden.

Blood